This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
by Zacks Equity Research
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
Karuna (KRTX) Stock Skyrockets 98.7% in a Month: Here's Why
by Zacks Equity Research
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook
by Zacks Equity Research
Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat
by Zacks Equity Research
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.
Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data
by Zacks Equity Research
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Can Morphic Holding, Inc. (MORF) Climb 97% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 96.7% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 9.21% and -47.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Morphic Holding, Inc. (MORF) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 16th
by Zacks Equity Research
CLMT, FANH, and MORF have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2021.
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Morphic Holding, Inc. (MORF) Q2 Earnings Expected to Decline
by Zacks Equity Research
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -6.78% and -45.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to Decline
by Zacks Equity Research
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morphic Holding, Inc. (MORF) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -54.05% and -26.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?